Countdown to 2020 CBIIC:

Introduction of 2020 CBIIC

China BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote the communication between pharmaceutical industry and investment industry, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of pharmaceutical industry, CBIIC focuses on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. CBIIC was built as an authorized, comprehensive, professional and international high level platform for the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation and discuss new investment channels and innovative cooperation strategies.

Established by PhIRDA, CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), Research and Development International (RDI) from 2016 to 2019. By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, including 80 international projects. CBIIC received extensive attention and was praised as the “most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region”.

To promote the in-depth cooperation between global capital and pharmaceutical innovation in China under the background of COVID-19, facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs, jointly building the new pattern of post-pandemic era for pharmaceutical industry, PhIRDA will host 2020 CBIIC in Suzhou Industrial Park on September 27-29, 2020.

I. Implement the Pharmaceutical Innovative Concept and Improve Setting of Parallel Sessions

To improve China’s biopharmaceutical innovation ability in all levels, biopharmaceutical industry has been included into the national central pillar industries for the first time on the Standing Committee of the Political Bureau of the Central Committee of the CPC in 2020. 2020 CBIIC will further open financing channel for pharmaceutical innovation, focus on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. 2020 CBIIC will include almost 20 fascinating and excellent parallel sessions such as Clinical Trial Data Release, Roadshows for Listed and Non-Listed Companies, Medical Devices, International Oncology Drugs, International Projects, WIT MED + Big Data, Artificial Intelligence (AI) + BioMed, Service Companies (CRO/CMO/CDMO) and Service Agencies and forums for Investors’ Experience Sharing, Financing M&A and Latest Drug Policy Sharing. The roadshow projects will cover the cutting-edge areas including biopharmaceutical, oncology drugs, orphan drugs, immunotherapy, AI for drug design, biotechnology, Virtual Healthcare, medical big data, gene detection, innovative medical devices, meeting diversified needs of participants.

II. Great Supports from National Authorized Institutions & In-depth Cooperation with Global Top Leading Organizations

2020 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China’s capability on transformation and innovation in pharmaceutical industry.

Since its establishment, CBIIC has received great support from prestigious institutions in China and around the world, including Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authorized academic institutions; Canada, the Netherlands, Australia and other embassies and consulates in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan supports CBIIC as the exclusive international financial institution sponsor for several times.

III. One-on-One Partnering System Provides Close Communication for Participants

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2020 CBIIC will build a better and more diverse platform for project presentation and communication. One-on-One partnering service will be provided for participants. Investors and roadshow speakers could propose an invitation in this system online easily and efficiently. In this event, participants will have face-to-face communication and negotiation to seek potential opportunities for further collaboration.

IV. Great Attention from Domestic and Global Medias and Witness the Integration of Innovation and Investment

Since 2016, CBIIC was supported by over ten well-known magazines and traditional medias at home and abroad, including Nature, people.cn, JKB.com.cn, China Pharmaceutical News , Medicine Economic Reporter, and attracted new medias and healthcare financial medias including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time report of the event and witness the integration of innovation and investment.

Under the great support of all parties, CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circle, present pharmaceutical innovative achievements at home and abroad, lead new investment trends. As the most influential annual grand conference in Asia-Pacific region, CBIIC will make social capital playing a leading role in the development of pharmaceutical innovation, create a more scientific and attractive investment environment and contribute to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

————

2100+

Pharmaceutical Companies

————

1500+

Investment Institutions

————

10000+

Participants

————

20+

Parallel Sessions & Forums

————

33+

Clinical Trial Data Release

————

450+

Innovative Projects